Separate names with a comma.
From Twitter: [ATTACH]
I have to admit your trolling is kinda fun and entertaining! Please, keep doing it!
God dammit, this is really getting more and more ridiculous every day. Honestly, I don't know if you're asking this seriously or you're just...
I was worried about you! Glad you're finally back so we can all enjoy your bullshit again :)
He asked her when the device could be available in Europe, not when an European trial would start, if any. That is indeed a stupid question since...
Keep bombing her with stupid questions rather than letting her do her f job. No wonder she'll blow it all before she completes the device. Then of...
Agreed, but new hair cells are expected to create new synaptic connections, too. I guess we'll have to wait...
So the drug's aiming to fix the synaptic connections, isn't it? Cool, then, we got a new player on the board (the fourth? fifth?), although it's a...
Frustrating is you all flooding the thread asking the same questions over and over again that have been answered dozens of times. Not to mention...
Probably not, but we don't know for sure yet. As you say, you need to have enough progenitor cells for the treatment to work (if it works at all).
By the way, paper is 3.5 years old.
Nope, Frequency's phase 1 took place in Australia as it is remarked in the piece.
Daily Mail is running a piece on hair cell regeneration: Could this new jab mean the end of hearing aids? Experimental treatment injected into...
Am I the only one who has this message at the bottom of the screen? [ATTACH] Cause I think I'm not and you all are ruining the whole thread with...
By the way, what are your thoughts on this?
Still no clue if it's just for "acute" tinnitus as we suppose. I'm not very excited about this kind of approach.
Cool thing! "Mid 2019" is actually pretty soon, though I wish it all could go even faster.
Tinnitus is now officially mentioned as potential indication for XEN1101, though they haven't disclosed any concrete plan for a specific trial...
Affichem's working on that, too.
What we know so far is that the drug induce the supporting cells to split into more supporting cells and actual hair cells. Does this mean that...
I think she wanted to be prudent rather than hopeful. Actually, I found her message quite positive for the coming years.
Besides Otonomy, there are at least two other companies that I'm aware of that are working on ribbon synapse regeneration, and one of them is...
I mean, do the researchers know whether the device can be used daily or not?
What if you use it every day?
Says the narcissistic one who recommends on his own website to get a ordinary $25k stem cells treatment in some Asian country that isn't based on...
Well deserved, I think.
Besides the above, in Europe we have actual national health systems that will pay for it ;)
Breakthrough drugs offer hope for the 360 million people with hearing loss Phase 2 is expected to start in the second half of the year:
Can you all stop spreading misinformation? Co-founder David Lucchino himself said several times that the drug could be on the market in three to...
I hope there won't be any DLC after the initial injection! :ROFL:
I guess that they were unable to observe efficacy (that is, if the drug successfully induced the body to create new hair cells, since I think this...
Yep, which should start before September 2018.
They have published a new video on AF243: [MEDIA] [ATTACH]
Yeah, I thought this, too. But if CGF166 end up being successful, can't they simply look for another less invasive delivery method (something like...
I know how the peer-review method works. I publish my own papers in economics journals. Maybe the word "scheduled" wasn't the most accurate one....
By the way, the second paper was scheduled to be published this year. I guess it's been pushed back to 2018?
A big online newspaper ran an article on tinnitus and Ménière yesterday ("That's what it's like to live with an ear beep 24 hours a day: "There...
The summit took place a month ago. I couldn't find anything on the web, though.
SENS-401 drug candidate During the first half of 2017, the Company successfully completed a phase 1 clinical trial establishing the safety of...
Why would they? People with tinnitus can still be healthy enough to be enrolled in a phase 1's safety trial. I bet they won't mention tinnitus...
Huge news!
Audion's approach does reduce some of your supporting cells, but not all of them.
Good luck! :)
Exactly. I'd expect OTO-311 to be as a failure as AM-101 (by the way, I think it's focused on "acute" tinnitus). I'm way more interested in their...
Otonomy: Advance Development of Multiple Programs for Hearing Loss and Tinnitus: Otonomy plans to continue the development of multiple programs...
Otonomy Announces Plan to Focus Resources on Development Programs Key Elements of Business Plan [...] Advance Development of Multiple Programs...
Sinking ship full of shit, as I expected. What a perfect time to share again this fantastic article!...
Maybe he's clairvoyant!
Nice advertising story! It truly is hilarious. Their drugs are terrific and unique (though AM-101 failed to show efficacy several times, but of...
Speak for yourself. I'm 100% sure my ears were destroyed at cellular level and thus tinnitus (and severe sudden hearing loss, which lasted 16-18...
From their presentation at Stifel 2017 Healthcare Conference: [ATTACH] [ATTACH]
From their financial report:
At least he's funny... or trying to! I suggest you all not to waste a single more minute with him ;)
It's already happening.
Sometimes I truly think guys like these really don't deserve any kind of cure or even some relief. Truly. They're not only spreading their...
It's not a scam, lol. The drug may or may not work, but it's based on actual research.
You got him wrong! Of course he was aware of that clinic two hours away, but it was not his, so he couldn't milk more money from you! :LOL:
Xenon Pharmaceuticals Announces Initiation of XEN1101 Phase 1 Clinical Trial Pharmacodynamic read-out expected in Q1 2018 and XEN1101 Phase 2...
Sadly, I wouldn't expect anything. It's a meeting for investors to explore new opportunities to invest in, not a TED-like presentations. Yes, they...
Short radio interview with CEO David Lucchino (from minute 28). Nothing new, though still interesting.